New combo therapy shows promise for First-Line CLL treatment
NCT ID NCT03609593
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested a combination of bendamustine and rituximab (BR) followed by venetoclax in 42 people with untreated chronic lymphocytic leukemia (CLL). The goal was to see how many patients responded to the full 15-month treatment. Venetoclax is an oral drug that targets a protein on CLL cells, but it can cause a dangerous side effect called tumor lysis syndrome, so dosing was carefully stepped up.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bendamustine, rituximab, and venetoclax
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for chronic lymphocytic leukemia, potentially leading to longer remission without needing continuous therapy.
- What could go wrong
- This is a small, single-arm phase 2 trial with only 42 participants, so results may not apply to all patients. There is a risk of tumor lysis syndrome, a serious side effect from rapid cell destruction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?